Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 926-943

  Obradovic, Marko ^a   Ikenberg, Robert ^b   Hertel, Nadine ^b   Antoñanzas, Fernando ^c   Gálvez, Rafael ^d   Liedgens, Hiltrud ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b IQVIA   (United States)

^c UNIVERSITY OF LA RIOJA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Chronic pain; Cost effectiveness; Modeling; Tapentadol

Indexed keywords

FENTANYL; MORPHINE; OXYCODONE; TAPENTADOL;

ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MULTIPLE CYCLE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SPAIN;

ANALGESICS, OPIOID; COST-BENEFIT ANALYSIS; HUMANS; PHENOLS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU; SPAIN;

EID: 84859613892     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.011     Document Type: Article

References (48)

1. Loeser J.D., Melzacka R. Pain: an overview. Lancet 1999, 353:1607-1609.
2. Turk D.C., Okifuji A. Pain terms and taxonomies of pain. Bonica's management of pain 2001, Lippincott Williams & Wilkins, Hagerstwon, MD. J.J. Bonica, J.D. Loeser, C.R. Chapman, D.C. Turk, S.H. Butler (Eds.).
3. Nicholson B., Passik S.D. Management of chronic non-cancer pain in the primary care setting. South Med J 2007, 100:1028-1036.
4. Breivik H., Collett B., Ventafridda V., et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006, 10:287-333.
5. Galer B.S., Dworkin R.H. A Clinical Guide to Neuropathic Pain 2000, McGraw-Hill, Minneapolis, Minn.
6. Freynhagen R., Baron R., Gockel U., et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006, 22:1911-1920.
7. Gilron I., Max M.B. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005, 5:823-830.
8. Phillips C. Economic burden of chronic pain. Expert Rev of Pharmacoecon Outcomes Res 2006, 6:591-601.
9. Katz W.A., Barkin R.L. Dilemmas in chronic/persistent pain management. Am J Ther 2008, 15:256-264.
10. Rowbotham M.C., Lindsey C.D. How effective is long-term opioid therapy for chronic noncancer pain?. Clin J Pain 2007, 23:300-302.
11. Kalso E., Edwards J.E., Moore R.A., et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004, 112:372-380.
12. Trescot A.M., Helm S., Hansen H., et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008, 11(Suppl 2):S5-S62.
13. McDermott A.M., Toelle T.R., Rowbotham D.J., et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006, 10:127-135.
14. Eriksen J., Sjøgren P., Bruera E., et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 2006, 125:172-179.
15. The white paper on opioids and pain: a pan-European challenge. J Pain Palliat Care Pharmacother 2006, 20:79-87. OPEN Minds (Opioids and Pain European Network of Minds).
16. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003, 63:17-32.
17. Harris J.D. Management of expected and unexpected opioid-related side effects. Clin J Pain 2008, 24:8-13.
18. Palexia Retard (tapentadol hidrocloruro) 100 mg comprimidos de liberación prolongada. Grünenthal Pharma, S.A.: Summary of product characteristics Agencia Española de Medicamentos y Productos Sanitarios, Accessed November 5, 2011. https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=73244&formato=pdf&formulario=FICHAS.
19. Tzschentke T.M., De Vry J., Terlinden R., et al. Tapentadol HCI. Drugs Future 2006, 31:1053-1061.
20. Tzschentke T.M., Christoph T., Kogel B., et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007, 323:265-276.
21. Afilalo M., Etropolski M.S., Kuperwasser B., et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010, 30:489-505.
22. Buynak R., Shapiro D.Y., Okamoto A., et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010, 11:1787-1804.
23. Lange B., Kuperwasser B., Okamoto A., et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010, 27:381-399.
24. Schwartz S., Etropolski M., Shapiro D.Y., et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011, 27:151-162.
25. Upmalis D, Okamoto A, Van Hove I, et al. Efficacy and tolerability data supporting the use of tapentadol immediate release for the relief of pain from end-stage joint disease. Annual EULAR Congress; June 11-14, 2008; Paris France. Abstract AB0744.
26. Oh C, Upmalis D, Okamoto A, et al. Flexible use of tapentadol immediate release for 90 days for the treatment of low back pain and osteoarthritis pain: a safety study. Annual EULAR Congress; June 11-14, 2008; Paris, France. Abstract FRI0335.
27. Hartrick C., Van Hove I., Stegmann J.U., et al. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009, 31:260-271.
28. Tzschentke T.M., Jahnel U., Kogel B., et al. Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009, 45:483-496.
29. Wild J.E., Grond S., Kuperwasser B., et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010, 10:416-427.
30. Allan L., Richarz U., Simpson K., et al. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 2005, 30:2484-2490.
31. Langley P.C., Ruiz-Iban M.A., Molina J.T., et al. The prevalence, correlates and treatment of pain in Spain. J Med Econ 2011, 14:367-380.
32. Bassols A., Boscha F., Campillo M., et al. El dolor de espalda en la población catalana. Prevalencia, características y conducta terapéutica. Gac Sanit 2003, 17:97-107.
33. Casals M., Samper D. Efectividad, tolerabilidad y calidad de vida en el tratamiento del dolor crónico no oncológico, com tramadol de liberación controlada en dosis única diaria. Rev Soc Esp Dolor 2004, 11:129-140.
34. OxyContin (oxycodona hidrocloruro) 20 mg comprimidos de liberación prolongada, Mundipharma Pharmaceuticals S.L.: Summary of product characteristics Agencia Española de Medicamentos y Productos Sanitarios, Accessed November 5, 2011. https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=63447&formato=pdf&formulario=FICHAS.
35. Donner B., Zenz M., Tryba M., et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996, 64:527-534.
36. Subdirección General de Coordinación Administrativa 2001, Resultados de la gestión analítica en los hospitales del Instituto Nacional de la Salud GECLIF 2000, Instituto Nacional de la Salud, Madrid, Spain.
37. BOTplus WEB Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF), Accessed May 2010. http://www.portalfarma.com/home.nsf/cmPortalIngles.
38. Barbieri M., Drummond M., Willke R., et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005, 8:10-23.
39. Neighbors D., Bell T., Wilson J., et al. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. Pain Symptom Manage 2001, 21:129-143.
40. Lehmann K., Radbruch L., Gockel H., et al. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur J of Health Econ 2003, 3:111-119.
41. Greiner W., Lehmann K., Earnshaw S., et al. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ 2006, 7:290-296.
42. Frei A., Andersen S., Hole P., et al. A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 2003, 17:5-26.
43. Steigerwald I, Kress GH, Kern U, et al. Effectiveness of tapentadol prolonged release for the management of severe, chronic low back pain with or without a neuropathic component. NWACWorld Anesthesia Congress; April 11-15, 2011; Rome, Italy. Abstract 067 plus poster.
44. Steigerwald I, Groblschegg S, Samper D, et al. Effectiveness of tapentadol prolonged release for the management of severe, chronic low back pain by prior opioid experience. Annual Meeting of the British Pain Society; June 21-24, 2011; Edinburgh, Germany. Abstract plus poster.
45. Summers K.H., Amy Puenpatom R., Rajan N., et al. Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ 2011, 14:390-396.
46. Langley P., Müller-Schwefe G., Nicolaou A., et al. The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. J Med Econ 2010, 13:662-672.
47. Gregorian R.S., Gasik A., Kwong W.J., et al. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain 2010, 11:1095-1108.
48. Chancellor J., Martin M., Liedgens H., et al. Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids. Value Health 2012, 15:106-117.